scholarly journals Validation of the Italian version of Mini-ICF-APP, a short instrument for rating activity and participation restrictions in psychiatric disorders

2012 ◽  
Vol 22 (1) ◽  
pp. 81-91 ◽  
Author(s):  
M. Balestrieri ◽  
M. Isola ◽  
R. Bonn ◽  
T. Tam ◽  
A. Vio ◽  
...  
Keyword(s):  
Psychosocial Functioning ◽  
Convergent Validity ◽  
Rating Scale ◽  
Social Performance ◽  
International Classification Of Functioning ◽  
Italian Version ◽  
Participation Restrictions ◽  
Schizophrenic Patients ◽  
Psychiatric Rating ◽  
Psychiatric Rating Scale

Aims.The assessment of limitations in social capacities can be done with the Mini-ICF-APP, a rating scale built in reference to the International Classification of Functioning, Disability and Health (ICF). The aim of this study was to assess the reliability and the convergent validity of the Italian version of this scale.Methods.We recruited 120 consecutive patients diagnosed with schizophrenia, major depression, bipolar I disorder and anxiety disorders. Included measures were the Brief Psychiatric Rating Scale (BPRS), the Clinical Global Impression Scale (CGI-S), the Personal and Social Performance Scale (PSP) and the Social and Occupational Functioning Assessment Scale (SOFAS).Results.The median CGI-S and BPRS scores were 5 and 16.5. Mean Mini-ICF-APP total score was 18.1. Schizophrenics' Mini-ICF-APP score was higher, while that of anxious patients was lower than in the other diagnoses. Intra-class correlations (ICC) revealed a significant inter-rater agreement for total score (ICC 0.987) and for each item of the Mini-ICF-APP. The test–retest agreement was also highly significant (ICC 0.993). The total score of the Mini-ICF-APP obtained good negative correlations with PSP (rs = −0.767) and with SOFAS scores (rs = −0.790). The distribution items of the Mini-ICF-APP showed some skewness, indicating that self-care (item 12) and mobility (item 13) were amply preserved in most patients. The Mini-ICF-APP total score was significantly correlated with both CGI-S (rs = 0.777) and BPRS (rs = 0.729).Conclusions.As a short instrument, the Mini-ICF-APP scale seems to be well suited to everyday psychiatric practice as a means of monitoring changes in psychosocial functioning, in particular in schizophrenic patients.

Factor–structure of the Italian version of the Scale Of Prodromal Symptoms (SOPS): a comparison with the English version

2011 ◽  
Vol 20 (1) ◽  
pp. 45-54 ◽  
Author(s):  
A. Comparelli ◽  
V. Savoja ◽  
G. D. Kotzalidis ◽  
S. W. Woods ◽  
S. Mosticoni ◽  
...  
Keyword(s):  
Psychometric Properties ◽  
Factor Structure ◽  
Convergent Validity ◽  
Rating Scale ◽  
Structured Interview ◽  
Italian Version ◽  
Prodromal Symptoms ◽  
Early Intervention Services ◽  
Psychiatric Rating ◽  
Psychiatric Rating Scale

Aims.The 19-item ‘Scale Of Prodromal Symptoms’ (SOPS) and its semi-structured interview, the Structured Interview for Prodromal Symptoms (SIPS), have been developed to assess prodromes of psychosis. We assessed psychometric properties of the Italian version of the instrument.Methods.We collected socio-demographic and clinical data of 128 people seeking first-time psychiatric help in a large Roman area, either as outpatients at community facilities or as inpatients in psychiatric wards of two general hospitals. Participants were administered the Italian version of the SOPS and the 24-item Brief Psychiatric Rating Scale (BPRS). Data were analysed through Pearson's correlation and factorial analysis.Results.The English and Italian SOPS versions showed similar psychometric properties and factorial structure. The best-fit model was trifactorial, explaining 90% of total variance, and roughly corresponding to the positive, negative, and general dimensions, with disorganisation spreading over the other dimensions. Compared with the BPRS, the Italian version of the SOPS showed construct validity and convergent validity.Conclusions.The factor–structure of the Italian version of the SOPS is similar to those of the English and Spanish versions, in that the factors emerged are the same (positive, negative, and general symptoms). The scale could be used to assess at-risk people in early intervention services.

scholarly journals Exploring the Factorial Structure of the Clinician-Rated Dimension of Psychosis Symptom Severity (CRDPSS-DSM-5) in Patients with Schizophrenia

2020 ◽  
Vol 28 (15) ◽  
pp. 30-49
Author(s):  
إبراهيم بن عبده صعدي إبراهيم بن عبده صعدي
Keyword(s):  
Internal Consistency ◽  
Symptom Severity ◽  
Convergent Validity ◽  
Rating Scale ◽  
Factorial Structure ◽  
Affective Symptoms ◽  
Schizophrenic Patients ◽  
Psychiatric Rating ◽  
Psychiatric Rating Scale ◽  
Negative Syndrome

The present study aimes to explore the factorial structure and the internal consistency of the Clinician-Rated Dimension of Psychosis Symptom Severity (CRDPSS) on a sample of Saudi schizophrenic patients. The sample consisted of 160 participants: 80 schizophrenic patients their ages ranged between 18 and 60 years old (M= 33.82 & SD= 9.70), and 80 participants as a matched group their ages ranged between 18 and 63 years old (M= 33.94 & SD= 9.12). The following measurements were utilized: 1- Positive and Negative Syndrome Rating Scale (PANSS), 2- Brief Psychiatric Rating Scale (BPRS), and 3- the CRDPSS. The results indicated that the CRDPSS comprised three factors (positive symptoms, negative/cognitive symptoms, and affective symptoms. Furthermore, the results revealed that the CRDPSS has significantly discriminate between disordered and normal participants. Moreover, the results showed that the convergent validity of the CRDPSS with PANSS and BPRS. Finally, the CRDPSS has showed significant high internal consistency.

Symptomatic Response to Antipsychotics Differs between Recent Onset and Recurrent Chronic Schizophrenic Patients

1992 ◽  
Vol 26 (3) ◽  
pp. 417-422 ◽  
Author(s):  
Christine Hill ◽  
Nicholas A. Keks ◽  
Henry Jackson ◽  
Jayashri Kulkarni ◽  
Deborah Hannah ◽  
...  
Keyword(s):  
Negative Symptoms ◽  
Rating Scale ◽  
Active Phase ◽  
Retardation Factor ◽  
Antipsychotic Treatment ◽  
Recent Onset ◽  
Schizophrenic Patients ◽  
Psychiatric Rating ◽  
Psychiatric Rating Scale ◽  
First Admission

The symptomatic response to standard antipsychotic treatment was assessed over the first 4 weeks of hospitalisation in 39 patients with DSM-III schizophrenia, active phase, using the Brief Psychiatric Rating Scale (BPRS). While highly significant improvement was noted overall, 36% of patients either did not improve or worsened. Furthermore there was no diminution in the withdrawal-retardation factor of the BPRS. Patients experiencing their first admission to hospital, all with recent-onset illness, were then compared with patients who presented with a recurrence and had illness of at least 3 years duration. Despite similarities in overall response, withdrawal-retardation scores did not diminish in recent-onset patients, in contrast to multiple admissions who demonstrated significant improvement. These findings suggest greater responsiveness of negative symptoms to treatment in patients with longstanding illness, and possibly a poorer prognosis in first admission patients with deficit manifestations.

Specific cognitive flexibility rehabilitation in schizophrenia

1993 ◽  
Vol 23 (1) ◽  
pp. 221-227 ◽  
Author(s):  
Ann Delahunty ◽  
Rodney Morice ◽  
Barry Frost
Keyword(s):  
Cognitive Flexibility ◽  
Test Performance ◽  
Rating Scale ◽  
Wisconsin Card Sorting Test ◽  
Card Sorting ◽  
Training Approach ◽  
Schizophrenic Patients ◽  
Psychiatric Rating ◽  
Psychiatric Rating Scale ◽  
Performance Gains

SynopsisA Cognitive Shift neurocognitive training module was developed in the attempt to ameliorate cognitive flexibility deficits in chronic schizophrenic patients. A procedural training approach hypothesized the exercise of specific neural network processes, identified from theories of frontal and prefrontal lobe functioning. Three male patients who underwent the intensive program demonstrated significant gains in Wisconsin Card Sorting Test performance, gains that were maintained at a six month reassessment. Expanded Brief Psychiatric Rating Scale (a measure of symptomatology) and Life Skills Profile (a measure of daily functioning) measures showed smaller improvements. The ability to improve cognitive flexibility could have important implications for the treatment of schizophrenia.

Sécurité d’emploi, tolérance et efficacité du palmitate de palipéridone à doses flexibles chez des patients schizophrènes hospitalisés pour une décompensation psychotique

2015 ◽  
Vol 30 (S2) ◽  
pp. S150-S150
Author(s):  
L. Hartgarter ◽  
M. Lahaye ◽  
P. Cherubin ◽  
A. Schreiner
Keyword(s):  
Rating Scale ◽  
Extrapyramidal Symptom ◽  
Social Performance ◽  
Satisfaction Questionnaire ◽  
Brief Psychiatric Rating Scale ◽  
Clinical Global Impression Severity ◽  
Psychiatric Rating ◽  
Psychiatric Rating Scale ◽  
Symptom Rating ◽  
Performance Scale

ObjectifExplorer sécurité d’emploi, tolérance et efficacité du palmitate de palipéridone (PP) à doses flexibles chez des patients adultes schizophrènes hospitalisés pour une décompensation.MéthodesÉtude internationale, prospective, en ouvert, non-interventionnelle de 6 semaines.ÉvaluationÉchelles BPRS (Brief Psychiatric Rating Scale), CGI-S (Clinical Global Impression-Severity), PSP (Personal and Social Performance Scale), questionnaire de satisfaction sur le traitement (MSQ-Medication Satisfaction Questionnaire), ESRS (Extrapyramidal Symptom Rating Scale) et évènements indésirables sous traitement (EIST), entre début d’étude (baseline) et dernière observation rapportée.RésultatsTrois cent soixante-sept patients analysés (65,9% hommes, âge moyen (± écart-type) 39,8 ± 12,1 ans, 85,8% schizophrénie paranoïde). Au total, 91,6% des patients ont terminé l’étude de 6 semaines. Le délai moyen entre l’admission à l’hôpital et l’initiation du PP était de 9,4 ± 7,7 jours. Le score initial BPRS (50,2 ± 13,6) s’est amélioré de–6,5 ± 8,6 au jour 8 et de–19,3 ± 12,6 à la fin de l’étude (IC 95% = –20,7;–18,0; deux critères avec p < 0,0001). En fin d’étude, 93,6% des patients étaient évalués comme améliorés sur l’échelle CGI-S. Le score de fonctionnement PSP s’est amélioré de 49,4 ± 14,7 à baseline à 14,3 ± 12,4 en fin d’étude (IC 95% = 12,9; 15,8, p < 0,0001). Le score ESRS moyen a diminué de manière significative de 3,7 ± 5,9 (baseline) à 2,0 ± 4,7 en fin d’étude (p < 0,0001). Le pourcentage de patients très ou extrêmement satisfaits par leur traitement antipsychotique est passé de 6,0% à baseline (traitement précédent) à 46,1% en fin d’étude (PP). EIST rapportés chez ≥ 2% des patients: tremblements (2,5%) et schizophrénie (2,2%).ConclusionsCes données chez des patients schizophrènes hospitalisés pour décompensation confirment les résultats d’études contrôlées randomisées montrant que le PP à doses flexibles est bien toléré, induit une réponse au traitement rapide et cliniquement significative et une amélioration du fonctionnement. Traduction de l’abstract résumé présenté au congrès EPA 2015 (European Congress of Psychiatry – Vienna, Austria, 28–31 March 2015).

Effect of an Open-Door Policy Combined with a Structured Activity Programme on the Residual Symptoms of Schizophrenic In-Patients

1994 ◽  
Vol 165 (S24) ◽  
pp. 52-57 ◽  
Author(s):  
Zhengshu Jin
Keyword(s):  
Negative Symptoms ◽  
Rating Scale ◽  
Control Group ◽  
Open Door Policy ◽  
Residual Symptoms ◽  
Schizophrenic Patients ◽  
Psychiatric Rating ◽  
Psychiatric Rating Scale ◽  
And Control ◽  
Experimental Group

Fifty female schizophrenic patients on the same locked ward were randomly assigned to experimental and control groups. Experimental group subjects were given as much autonomy and freedom as possible (they were permitted to leave the ward at will) and were encouraged to take part in collective activities. The control group were not permitted to leave the ward and did not take part in these activities. All patients were evaluated at enrolment and after six months – using Chinese versions of the Scale for Assessment of Negative Symptoms and the Brief Psychiatric Rating Scale – by psychiatrists who were blind to patients' treatment status. After the six-month intervention the severity of all types of both negative and positive symptoms and the mean dosage of medication in the experimental group were significantly less than in the control group.

Propranolol in Chronic Schizophrenia: A Controlled Study in Neuroleptic-Treated Patients

1980 ◽  
Vol 137 (2) ◽  
pp. 126-130 ◽  
Author(s):  
Leif H. Lindström ◽  
Eva Persson
Keyword(s):  
Rating Scale ◽  
Chronic Schizophrenia ◽  
Placebo Treatment ◽  
Controlled Study ◽  
Psychotic Symptoms ◽  
Double Blind ◽  
Schizophrenic Patients ◽  
Psychiatric Rating ◽  
Psychiatric Rating Scale ◽  
High Doses

The effect of propranolol at a dose level of 1,280–1,920 mg per day was studied with a double-blind crossover design in twelve chronic schizophrenics with persistent psychotic symptoms despite maintenance treatment with a depot neuroleptic. By use of a psychiatric rating scale (CPRS), an improvement was seen during the two week period of propranolol compared to placebo treatment in six patients, whereas three patients were unchanged and three deteriorated. The effect on total symptom scores for the whole group was significantly better after propranolol. The data indicate that propranolol in high doses has an antipsychotic effect in some schizophrenic patients when receiving neuroleptics.

An open trial of clozapine in neuroleptic-resistant childhood-onset schizophrenia

1997 ◽  
Vol 170 (6) ◽  
pp. 507-510 ◽  
Author(s):  
M. Turetz ◽  
T. Mozes ◽  
P. Toren ◽  
T. Chernauzan ◽  
R. Yoran-Hegesh ◽  
...  
Keyword(s):  
Rating Scale ◽  
Favourable Outcome ◽  
Childhood Onset ◽  
Conventional Antipsychotics ◽  
Syndrome Scale ◽  
Increased Risk ◽  
Childhood Onset Schizophrenia ◽  
Schizophrenic Patients ◽  
Psychiatric Rating ◽  
Psychiatric Rating Scale

BackgroundStudies performed with schizophrenic adults who were resistant to classical neuroleptics showed improvement in 30% of the patients when treated with clozapine. Very early onset schizophrenic patients benefit only partially from conventional antipsychotics and are at increased risk of developing extrapyramidal symptoms; clozapine may offer an alternative treatment for these patients.MethodEleven neuroleptic-resistant children (< 13 years) with schizophrenia were treated with clozapine. Improvement was monitored during the first 16 weeks using the Brief Psychiatric Rating Scale, Positive and Negative Syndrome Scale and Clinical Global Impression. The mean clozapine dosage was 227.3 (s.d. 34.4) mg/day at the end of the 16 weeks.ResultsThere was an overall statistically significant reduction in all parameters, especially positive symptoms, implying a favourable outcome. Most of the improvement occurred during the first 6 to 8 weeks. The major side-effects were somnolence and drooling (no agranulocytosis).ConclusionClozapine may be a promising drug for the treatment of resistant childhood-onset schizophrenia.

Obsessive-compulsive symptoms induced by atypical anti-psychotics

2011 ◽  
Vol 26 (S2) ◽  
pp. 1220-1220
Author(s):  
A. Afkhamebrahimi
Keyword(s):  
Rating Scale ◽  
Obsessive Compulsive ◽  
Obsessive Compulsive Symptoms ◽  
Brief Psychiatric Rating Scale ◽  
Schizophrenic Patients ◽  
Psychiatric Rating ◽  
The Mean ◽  
Psychiatric Rating Scale ◽  
In The Beginning ◽  
The Impact

ObjectiveThe impact of typical and atypical anti-psychotics on developing obsessive-compulsive symptoms in schizophrenic patients were investigated in this study.Materials and methods64 schizophrenic patients (32 cases in typical anti-psychotics group and 32 in atypical anti-psychotics group) participated in the study. All the patients first interviewed by SCID and then Yale Brown Obsessive-Compulsive Scale (Y-BOCS) and Brief psychiatric Rating Scale were administered in the beginning, 3 weeks and 6 weeks after treatment. The Data then transferred to SPSS program. for analysis.ResultsIn typical group the mean scores of Y-BOCS were 2.40, 2.30 and 2.18 in the beginning, 3 weeks and 6 weeks after treatment. In atypical group the mean scores of Y-BOCS were 4.12, 4.46 and 4.53 in three trials. There were no significant differences in the mean scores of Y-BOCS of two group in the beginning of the trial although a trend toward significance was observed but the differences between scores were significant in trial 2 (3 weeks) and trial 3 (6 weeks).DiscussionBased on this study and in line with previous studies, atypical anti-psychotics may induce obsessive compulsive symptoms (although mild) in patients with schizophrenia.

Sign in / Sign up

Export Citation Format

Share Document